Saturday, July 4, 2020

Merck announces efforts to combat COVID-19

By on June 26, 2020

SAN JUAN — Global pharmaceutical company Merck, known as MSD outside the United States and Canada, announce three initiatives Friday to combat COVID-19: two agreements to develop potential vaccines against SARS-CoV-2, and a research collaboration to advance the development of a novel antiviral candidate. 

Merck said it will acquire Themis Bioscience, a company focused on vaccines and immune-modulation therapies for infectious diseases, including COVID-19. The pharma giant also said it and IAVI were collaborating to develop a vaccine against COVID-19. In addition, it was collaborating with Ridgeback Bio to advance development of an oral antiviral candidate for COVID-19, EIDD-2801. 

“With our singular legacy and expertise in vaccines and anti-infective medicines, we know Merck has a responsibility to engage in the scientific community’s efforts to find new medicines and vaccines to bring this pandemic to an end,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “Merck has been fully committed to developing an effective response to the COVID-19 pandemic since it was first recognized, and we know that success will require global collaboration among countries and companies and more. Today, we are proud to mark the culmination of our swift, conscientious and concerted effort to identify some of the most promising solutions to this global challenge and to put our resources to use in accelerating these efforts. We will ensure that all of these programs have the resources, attention and focus they need – and that the COVID-19 pandemic demands.”

“COVID-19 is a global challenge and requires global solutions. Merck intends to make any vaccine or medicine we develop for this pandemic broadly accessible and affordable globally, and we are working now to accomplish this goal as quickly as possible. As we just demonstrated with our Ebola vaccine, when the world needs to come together to tackle new and daunting challenges, Merck can be counted on to do our part. Though the challenge of this pandemic is immense, we know that science and collaboration will triumph, just as they have before. While we cannot predict when this battle will be won, we are confident that science is on our side, that collaboration is already well underway, and that together, we will prevail.”